Edwards Lifesciences navigates the structural heart market with Q4 2024 results, TAVR/TMTT growth, and a strategic outlook. Upcoming TD Cowen conference insights.
Edwards Lifesciences (EW) Q4 2024 earnings beat expectations, driven by TAVR/TMTT growth. Margins face pressure, but analysts see long-term strength.
Edwards Lifesciences' Q4 2024 results demonstrate strong growth in TAVR and TMTT. Strategic focus on structural heart and margin management are key.
Edwards Lifesciences' Q4 2024 results reveal strong growth tempered by margin concerns. Focus shifts to structural heart and TMTT potential. Analyst outlook mixed. Strategic implications abound.
Edwards Lifesciences' Q4 results show growth tempered by margin concerns. Strategic shifts and market dynamics shape the outlook for EW in 2025.
Explore Edwards Lifesciences' Q4 2024 results, showcasing strong TAVR growth, TMTT innovation, and a strategic shift after divesting Critical Care.
Edwards Lifesciences focuses on structural heart strategy after critical care divestiture. Q4 earnings show strong growth, margin challenges, and TAVR/TMTT focus.
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides the PASCAL and Cardioband transcatheter valve repair systems for minimally-invasive therapy. In addition, it offers surgical structural heart solutions, such as aortic surgical valve under the INSPIRIS name; KONECT RESILIA, a pre-assembled aortic tissue valved conduit for patients who require replacement of the valve, root, and ascending aorta; and HARPOON Beating Heart Mitral Valve Repair System for patients with degenerative mitral regurgitation. Further, the company provides critical care solutions, including advanced hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; and Acumen Hypotension Prediction Index software that alerts clinicians in advance of a patient developing dangerously low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.